Clinical Trial

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-11-02; most recent amendment 2025-12-03.
Trial Details
NCT Number NCT06121180
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Conditions Metastatic Uveal Melanoma
Enrollment 32 participants
Start Date 2024-11-04
Primary Completion 2030-10-31 (estimated)
Study Completion 2030-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-04